Serotonergic Antidepressants and Hospitalization for Bleeding in Patients with LVAD

Association of bleeding with serotonergic antidepressants in patients receiving left ventricular assist device support

“…35 In addition, preliminary analysis of a retrospective study of 95 patients with CF-LVADs revealed a trend toward increased rate of hospitalization due to bleeding in patients treated with SA therapy. 34 Our study reaffirms the results of these previous studies in a much larger cohort, with a similar association of bleeding events in patients receiving SAs.…”

“…Although these data are observational, there are several strengths of our study in comparison to previous studies examining SA use in patients with CF-LVADs. We were able to include a significantly larger cohort than previously studied [33][34][35] including an appreciable number of HeartMate 3™ devices, which are being more frequently utilized given a favorable safety profile. We included many characteristics in our analyses that have been shown…”

“…[29][30][31][32] The degree to which SAs increase bleed risk in the CF-LVAD population has been infrequently studied. Three cohort studies have found an increased risk of experiencing GIB for CF-LVAD patients receiving SAs, though these studies have included small sample sizes, 33,34 no HeartMate 3™ devices, 33,35 and lacked analysis of other significant bleeding events including ICH or epistaxis. 33,35 Due to the sparse literature available regarding the association between bleeding and SA use in CF-LVAD patients, we sought to evaluate the impact of SA use on bleeding (GIB, ICH, and epistaxis) in patients supported with CF-LVADs.…”